Refine By

Stock Exchange

Market Cap (m)



Type of Publication


1 - 4 of 4
Sort by: popularity | newest
Page  of 1

H117 results show further business progress

Update | Pharmaceutical & healthcare | 06 Oct 2017

In H117 Formycon disclosed that FYB202 is a proposed biosimilar of Stelara and it recently announced that it is in the process of entering into a co-investment agreement with Santo Holding to advance FYB202 through regulatory approval. The global Phase III study of Lucentis biosimilar FYB201 for neovascular age-related macular degeneration (nAMD) is progressing according to plan with US and EU launches slated for 2020 and 2022. Lastly, FYB203 (Eylea biosimilar) and FYB205 (undisclosed) are advancing in preclinical studies. Cash and equity at end H117 was EUR 14.4m.


Building a pipeline of third-wave biosimilars

Update | Pharmaceutical & healthcare | 11 May 2017

Formycon has reported FY16 financial results that highlight the progress of its biosimilars pipeline. During 2016 partner Bioeq IP AG started a global Phase III study of Lucentis biosimilar FYB201 for neovascular age-related macular degeneration (nAMD); US and EU launches are planned for 2020 and 2022. Formycon disclosed that FYB203 is a proposed biosimilar of Eylea in preclinical studies. It targets all biologics in the nAMD market, which had revenues of $8.2bn in 2016. The company recently disclosed that FYB202 is a biosimilar of Stelara. Cash at end 2016 was €14m.


Surfing the next wave of biosimilars

Initiation | Pharmaceutical & healthcare | 27 Mar 2017

Formycon is a pure-play biosimilar company focused on third-wave biosimilars (those coming off patent after 2020), an overlooked opportunity for most biosimilar developers. The company has four compounds, two of which are partnered. FYB201 is a biosimilar of Lucentis for neovascular age-related macular degeneration (nAMD) undergoing a global Phase III study; the company is aiming for US and EU launch in 2020 and 2022, respectively, upon patent expiries. FYB203 is a proposed biosimilar of Eylea, also for nAMD, in preclinical studies. Both compounds are partnered in deals worth over EUR 100m and target all available biologics in the nAMD market. The liquidity position at end September 2016 was EUR 19m.


Biosimilar opportunities

QuickView | Pharmaceutical & healthcare | 07 Nov 2013

Formycon is preparing to exploit the emerging opportunity for biosimilars. By 2020, protein-based therapeutics with sales of >$70bn will lose patent protection. Its first two biosimilar programmes are progressing well and could be partnered in 2015. There should be significant demand for Formycon products because of the size of the markets and the challenges of developing biosimilar products with the correct characteristics.